Answers are grounded in this paper and cite their sources.
Real-world analysis reveals ocular toxicity and its predictors in patients receiving MIRV for ovarian cancer, indicating a need for monitoring.
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRα), approved for the treatment of patients with FRα-positive platinum-resistant ovarian cancer. Ocular adverse events are common with MIRV and may require dose modifications. Real-world data on incidence, predictors and clinical impact remain limited. Therefore, the aim of this study was to address these gaps, including their association with treatment response, in patients receiving MIRV in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Giustozzi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: